Holding(s) in Company

Haleon PLC

16 May 2023

 

16 May 2023

HALEON PLC 

​("Haleon" or "the Company")  

TR-1: Standard form for notification of major holdings ​ 

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

Haleon plc

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Glaxo Group Limited

City of registered office (if applicable)

Brentford

Country of registered office (if applicable)

United Kingdom

Name	City of registered office	Country of registered office
GlaxoSmithKline Holdings Limited	Brentford	England
GlaxoSmithKline Finance plc	Brentford	England

4. Details of the shareholder

Name	City of registered office	Country of registered office
Vidacos Nominees Limited	London	England

5. Date on which the threshold was crossed or reached

12-May-2023

6. Date on which Issuer notified

15-May-2023

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	2.850000	0.000000	2.850000	262727073
Position of previous notification (if applicable)	5.440000	0.000000	5.440000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BMX86B70	262727073		2.850000
Sub Total 8.A	262727073		2.850000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
GSK plc		2.850000		2.850000%
GSK plc	GlaxoSmithKline Holdings Limited	2.850000		2.850000%
GSK plc	GlaxoSmithKline Finance plc	2.850000		2.850000%
GSK plc	Glaxo Group Limited	2.850000		2.850000%

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

GSK plc is making this notification on behalf of Glaxo Group Limited, GlaxoSmithKline Finance plc and GlaxoSmithKline Holdings Limited.

This notification relates to the sale by Glaxo Group Limited (a wholly-owned subsidiary of GSK plc and the holder of other external minority interests of the GSK group) of a portion of its interest in Haleon plc. A separate notification has also been submitted today by GSK plc in respect of its own notification obligation.

Glaxo Group Limited holds its shares in Haleon plc via a custodian, Vidacos Nominees Limited (as detailed in section 4 above), which holds the legal title to those shares on Glaxo Group Limited's behalf pursuant to a custody arrangement.

12. Date of Completion

15-May-2023

13. Place Of Completion

London, England

Amanda Mellor, Company Secretary

 

END